Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix Hexa Immunogenicity and Safety in Healthy Infants
NCT02096263Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pertussis filamentous haemagglutinin in diphtheria, Tetanus, pertussis, hepatitis B (HBV), poliomyelitis, sponsored by GSK. Started Apr 2014; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT02096263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096263.